Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Common Equity (2016 - 2025)

Historic Common Equity for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $4.5 million.

  • Traws Pharma's Common Equity rose 32356.12% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 32356.12%. This contributed to the annual value of -$31.6 million for FY2024, which is 39638.31% down from last year.
  • As of Q3 2025, Traws Pharma's Common Equity stood at $4.5 million, which was up 32356.12% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Common Equity registered a high of $49.7 million during Q3 2021, and its lowest value of -$105.5 million during Q2 2024.
  • Its 5-year average for Common Equity is $13.7 million, with a median of $18.9 million in 2023.
  • In the last 5 years, Traws Pharma's Common Equity surged by 64688.26% in 2021 and then crashed by 65836.6% in 2024.
  • Quarter analysis of 5 years shows Traws Pharma's Common Equity stood at $46.1 million in 2021, then crashed by 38.62% to $28.3 million in 2022, then plummeted by 62.3% to $10.7 million in 2023, then crashed by 396.38% to -$31.6 million in 2024, then surged by 114.37% to $4.5 million in 2025.
  • Its Common Equity was $4.5 million in Q3 2025, compared to $8.3 million in Q2 2025 and $6.0 million in Q1 2025.